Thomas Martin, MD

Director of Clinical Research

Hematology and Oncology UCSF Health

Education
Post-Doc Fellow/Scholar, 1996 - Medicine, University of California, San Francisco
M.D., 1989 - School of Medicine, University of Connecticut
Clinical Fellowship, - , University of California, San Francisco
Residency, - , University of California, San Francisco
Websites
Publications
  1. Nawas MT, Sheng Y, Huang CY, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Olin RL. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation. 2020. PMID: 33059999


  2. Sherbenou DW, Su Y, Behrens CR, Aftab BT, Perez de Acha O, Murnane M, Bearrows SC, Hann B, Wolf JL, Martin TG, Liu B. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma. 2020. PMID: 32917735


  3. Ramkumar P, Abarientos AB, Tian R, Seyler M, Leong JT, Chen M, Choudhry P, Hechler T, Shah N, Wong SW, Martin TG, Wolf JL, Roybal KT, Pahl A, Taunton J, Wiita AP, Kampmann M. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma. 2020. PMID: 32589729


  4. Huang HH, Ferguson ID, Thornton AM, Bastola P, Lam C, Lin YT, Choudhry P, Mariano MC, Marcoulis MD, Teo CF, Malato J, Phojanakong PJ, Martin TG, Wolf JL, Wong SW, Shah N, Hann B, Brooks AN, Wiita AP. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma. 2020. PMID: 32321912


  5. Du Z, Weinhold N, Song GC, Rand KA, Van Den Berg DJ, Hwang AE, Sheng X, Hom V, Ailawadhi S, Nooka AK, Singhal S, Pawlish K, Peters ES, Bock C, Mohrbacher A, Stram A, Berndt SI, Blot WJ, Casey G, Stevens VL, Kittles R, Goodman PJ, Diver WR, Hennis A, Nemesure B, Klein EA, Rybicki BA, Stanford JL, Witte JS, Signorello L, John EM, Bernstein L, Stroup AM, Stephens OW, Zangari M, Van Rhee F, Olshan A, Zheng W, Hu JJ, Ziegler R, Nyante SJ, Ingles SA, Press MF, Carpten JD, Chanock SJ, Mehta J, Colditz GA, Wolf J, Martin TG, Tomasson M, Fiala MA, Terebelo H, Janakiraman N, Kolonel L, Anderson KC, Le Marchand L, Auclair D, Chiu BC, Ziv E, Stram D, Vij R, Bernal-Mizrachi L, Morgan GJ, Zonder JA, Huff CA, Lonial S, Orlowski RZ, Conti DV, Haiman CA, Cozen W. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. 2020. PMID: 31935283


  6. Shah EE, Young RP, Wong SW, Damon LE, Wolf JL, Shah ND, Leavitt AD, Loeffler P, Martin TG. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma. 2019. PMID: 31785375


  7. Martin TG, Corzo K, Chiron M, Velde HV, Abbadessa G, Campana F, Solanki M, Meng R, Lee H, Wiederschain D, Zhu C, Rak A, Anderson KC. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab. 2019. PMID: 31779273


  8. Choudhry P, Mariano MC, Geng H, Martin TG, Wolf JL, Wong SW, Shah N, Wiita AP. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma. 2019. PMID: 31595037


  9. Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Steinman MA, Huang CY, Olin RL. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients. 2019. PMID: 31493541


  10. Panowski SH, Kuo TC, Zhang Y, Chen A, Geng T, Aschenbrenner L, Kamperschroer C, Pascua E, Chen W, Delaria K, Farias S, Bateman M, Dushin RG, Chin SM, Van Blarcom TJ, Yeung YA, Lindquist KC, Chunyk AG, Kuang B, Han B, Mirsky M, Pardo I, Buetow B, Martin TG, Wolf JL, Shelton D, Rajpal A, Strop P, Chaparro-Riggers J, Sasu BJ. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma. 2019. PMID: 31434693


  11. Martin T, Huff CA. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Multiple Myeloma: Current Advances and Future Directions. 2019. PMID: 31130488


  12. Nawas MT, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Huang CY, Olin RL. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation. 2019. PMID: 30708189


  13. Leleu X, Martin TG, Einsele H, Lyons RM, Durie BGM, Iskander KS, Ailawadhi S. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma. 2018. PMID: 30287200


  14. Tan M, Kalin-Hajdu E, Narayan R, Wong SW, Martin TG. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma. 2018. PMID: 30005587


  15. Le Moigne R, Aftab BT, Djakovic S, Dhimolea E, Valle E, Murnane M, King EM, Soriano F, Menon MK, Wu ZY, Wong ST, Lee GJ, Yao B, Wiita AP, Lam C, Rice J, Wang J, Chesi M, Bergsagel PL, Kraus M, Driessen C, Kiss von Soly S, Yakes FM, Wustrow D, Shawver L, Zhou HJ, Martin TG, Wolf JL, Mitsiades CS, Anderson DJ, Rolfe M. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma. 2017. PMID: 28878026


  16. Vogl DT, Martin TG, Vij R, Hari P, Mikhael JR, Siegel D, Wu KL, Delforge M, Gasparetto C. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. 2017. PMID: 28140719


  17. Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf JL, Martin TG, Liu B. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. Volume 126 of Issue 12. 2016. PMID: 27841764


  18. Rand KA, Song C, Dean E, Serie DJ, Curtin K, Sheng X, Hu D, Huff CA, Bernal-Mizrachi L, Tomasson MH, Ailawadhi S, Singhal S, Pawlish K, Peters ES, Bock CH, Stram A, Van Den Berg DJ, Edlund CK, Conti DV, Zimmerman T, Hwang AE, Huntsman S, Graff J, Nooka A, Kong Y, Pregja SL, Berndt SI, Blot WJ, Carpten J, Casey G, Chu L, Diver WR, Stevens VL, Lieber MR, Goodman PJ, Hennis AJ, Hsing AW, Mehta J, Kittles RA, Kolb S, Klein EA, Leske C, Murphy AB, Nemesure B, Neslund-Dudas C, Strom SS, Vij R, Rybicki BA, Stanford JL, Signorello LB, Witte JS, Ambrosone CB, Bhatti P, John EM, Bernstein L, Zheng W, Olshan AF, Hu JJ, Ziegler RG, Nyante SJ, Bandera EV, Birmann BM, Ingles SA, Press MF, Atanackovic D, Glenn MJ, Cannon-Albright LA, Jones B, Tricot G, Martin TG, Kumar SK, Wolf JL, Deming Halverson SL, Rothman N, Brooks-Wilson AR, Rajkumar SV, Kolonel LN, Chanock SJ, Slager SL, Severson RK, Janakiraman N, Terebelo HR, Brown EE, De Roos AJ, Mohrbacher AF, Colditz GA, Giles GG, Spinelli JJ, Chiu BC, Munshi NC, Anderson KC, Levy J, Zonder JA, Orlowski RZ, Lonial S, Camp NJ, Vachon CM, Ziv E, Stram DO, Hazelett DJ, Haiman CA, Cozen W. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. Volume 25 of Issue 12. 2016. PMID: 27587788


  19. Mulé MP, Mannis GN, Wood BL, Radich JP, Hwang J, Ramos NR, Andreadis C, Damon L, Logan AC, Martin TG, Hourigan CS. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation. Volume 22 of Issue 11. 2016. PMID: 27544285


  20. Baz RC, Martin TG, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. 2016. PMID: 26932802


  21. Mannis GN, Martin TG, Damon LE, Andreadis C, Olin RL, Kong KA, Faham M, Hwang J, Ai WZ, Gaensler KML, Sayre PH, Wolf JL, Logan AC. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation. Volume 22 of Issue 6. 2016. PMID: 26899561


  22. Mannis GN, Martin TG, Damon LE, Logan AC, Olin RL, Flanders MD, Ai WZ, Gaensler KM, Kaplan LD, Sayre PH, Smith CC, Wolf JL, Andreadis C. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. Volume 57 of Issue 7. 2016. PMID: 26490487


  23. Mannis GN, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai WZ, Gaensler KM, Kaplan LD, Koplowicz YB, Linker CA, Olin RL, Sayre PH, Smith CC, Sudhindra A, Venstrom JM, Wolf JL, Martin TG. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. Volume 15 of Issue 6. 2015. PMID: 25776193


  24. Sherbenou DW, Behrens CR, Su Y, Wolf JL, Martin TG, Liu B. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. The development of potential antibody-based therapies for myeloma. 2014. PMID: 25294123


  25. Mannis GN, Logan AC, Leavitt AD, Yanada M, Hwang J, Olin RL, Damon LE, Andreadis C, Ai WZ, Gaensler KM, Greene CC, Gupta NK, Kaplan LD, Mahindra A, Miyazaki Y, Naoe T, Ohtake S, Sayre PH, Smith CC, Venstrom JM, Wolf JL, Caballero L, Emi N, Martin TG. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. Volume 50 of Issue 1. 2014. PMID: 25243620


  26. Keller JW, Andreadis C, Damon LE, Kaplan LD, Martin TG, Wolf JL, Ai WZ, Venstrom JM, Smith CC, Gaensler KM, Hwang J, Olin RL. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. 2014. PMID: 24894413


  27. Martin TG. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib. 2013. PMID: 25184230


  28. Niesvizky R, Martin TG, Bensinger WI, Alsina M, Siegel DS, Kunkel LA, Wong AF, Lee S, Orlowski RZ, Wang M. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. 2013. PMID: 23447001


  29. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Lenalidomide after stem-cell transplantation for multiple myeloma. 2012. PMID: 22571201


  30. Linker C, Damon L, Martin T, Blume K, Forman S, Snyder D, Wolf J, Negrin R. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Autologous hematopoietic cell transplantation for high-risk ALL. 2010. PMID: 20531287


  31. Damon L, Damon LE, Gaensler K, Kaplan L, Martin T, Rubenstein J, Linker C. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma. 2008. PMID: 18679366


  32. de Lima M, Champlin RE, Thall PF, Wang X, Martin TG, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. 2007. PMID: 17989720


  33. Lekakis L, Giralt S, Couriel D, Shpall EJ, Hosing C, Khouri IF, Anderlini P, Korbling M, Martin T, Champlin RE, de Lima M. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. 2006. PMID: 16892072


  34. Damon L, Rugo H, Tolaney S, Navarro W, Martin T, Ries C, Case D, Ault K, Linker C. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim. 2006. PMID: 16503501


  35. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, Khouri I, Andersson B, Gajewski J, Donato M, Anderlini P, Kontoyiannis DP, Cohen A, Martin T, Giralt S, Champlin R. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. 2004. PMID: 15069017


  36. Khorshid O, de Meis E, Martin T, Jones RB, Shpall EJ, Nieto Y, Khouri I, Shahjahan M, Gajewski J, Giralt S, Champlin R, de Lima M. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant. 2003. PMID: 14523458


  37. Gunn N, Damon L, Varosy P, Navarro W, Martin T, Ries C, Linker C. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia. 2003. PMID: 14569560


  38. Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C, Andersson BS, Cano P, Shahjahan M, Ippoliti C, Estey EH, McMannis J, Gajewski JL, Champlin RE, de Lima M. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. 2003. PMID: 12842990


  39. Thall PF, Inoue LY, Martin TG. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Adaptive decision making in a lymphocyte infusion trial. 2002. PMID: 12229990


  40. Hosing C, Munsell M, Yazji S, Andersson B, Couriel D, de Lima M, Donato M, Gajewski J, Giralt S, Körbling M, Martin T, Ueno NT, Champlin RE, Khouri IF. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. 2002. PMID: 11996478


  41. Martin TG, Gajewski JL. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults. 2001. PMID: 11253611


  42. Martin TG, Linker CA. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Autologous stem cell transplantation for acute lymphocytic leukemia in adults. 2001. PMID: 11253604


  43. Muench MO, Rae J, Bárcena A, Leemhuis T, Farrell J, Humeau L, Maxwell-Wiggins JR, Capper J, Mychaliska GB, Albanese CT, Martin T, Tsukamoto A, Curnutte JT, Harrison MR. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease. 2001. PMID: 11313664


  44. Shimoni A, Gajewski JA, Donato M, Martin T, O'Brien S, Talpaz M, Cohen A, Korbling M, Champlin R, Giralt S. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. 2001. PMID: 11760089


  45. Anderlini P, Donato M, Lauppe MJ, Huh YO, Martin TG, Chan KW, Champlin RE, Körbling M. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors. 2000. PMID: 10929027


  46. Martin TG, Shuman MA. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Interferon-induced thrombocytopenia: is it time for thrombopoietin. 1998. PMID: 9794932


  47. Martin TG, Somberg KA, Meng YG, Cohen RL, Heid CA, de Sauvage FJ, Shuman MA. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. 1997. PMID: 9265428


  48. Meng YG, Martin TG, Peterson ML, Shuman MA, Cohen RL, Wong WL. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation. 1996. PMID: 8943898


  49. Dimery IW, Brooks BJ, Winn R, Martin T, Shirinian M, Hong WK. Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.., Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma.., CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.., Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.., A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.., Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.., Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.., DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.., Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients.., Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.., Multiple Myeloma: Current Advances and Future Directions.., Limitation in Patient-Reported Function is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.., Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.., Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.., The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.., Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.., Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.., A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.., Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.., Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.., Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.., Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.., A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.., The development of potential antibody-based therapies for myeloma.., Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.., Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.., Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.., Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.., Lenalidomide after stem-cell transplantation for multiple myeloma.., Autologous hematopoietic cell transplantation for high-risk ALL.., Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.., Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.., Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.., Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.., Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.., High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.., Adaptive decision making in a lymphocyte infusion trial.., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.., Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults.., Autologous stem cell transplantation for acute lymphocytic leukemia in adults.., Transplantation of a fetus with paternal Thy-1(+)CD34(+)cells for chronic granulomatous disease.., Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.., Interferon-induced thrombocytopenia: is it time for thrombopoietin.., Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.., Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation.., Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck. 1991. PMID: 1941052